Globus Medical Inc. Class A Common Stock vs Stitch Fix Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Stitch Fix Inc trades at $2.38 (market cap $326.66M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 31.4× Stitch Fix Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Stitch Fix Inc for 31 Days on average.
| GMED | SFIX | |
|---|---|---|
Market Cap | $10.25B | $326.66M |
Volume | 1,108,124 | 3,004,657 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $5.64 |
52-Week Low | $58.33 | $2.16 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $9.76B | $222.46M |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Stitch Fix (SFIX) trades at $2.39, down 11.48% amid bearish technical signals and negative cash flow trends. The company shows improving fundamentals with three consecutive quarterly EPS beats and narrowing losses, though revenue remains stagnant at $1.27B. Recent news highlights fraud investigations and disappointing Q4 2026 results that missed revenue estimates, driving the stock's decline.
The outlook remains challenging with analyst consensus leaning neutral (69.7% hold) and a $3.40 price target suggesting limited upside. Key risks include ongoing legal scrutiny, weak FY27 guidance, and persistent net losses despite margin improvements. The stock's trajectory depends on reversing active client declines and achieving sustainable profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →